




Formulations



Toxicology

Research &  
Development




API & Intermediates






*22<sup>nd</sup> Annual Report*  
2010 - 2011

## Few of own Branded Products of your Company



## Few of own Branded Products of your Company



**Sharon's Staff Picnic at The Silent Hill Resort**



**Diwali Treat at Vashi**



---

## CONTENTS

---

Particulars	Pg. No.
Managing Directors' Letter	06
Notice	08
Directors' Report	10
Corporate Governance	16
Management Discussion & Analysis	27
Auditors' Report	29
Balance Sheet	32
Profit & Loss Account	33
Cash Flow Statement	34
Schedules	35
Balance Sheet Abstract	46
Reports and Accounts of the Subsidiary Company Yusur International FZE, UAE	47
Consolidated Financial Statement of Sharon Bio-Medicine Limited and Yusur International FZE	54

## **BOARD OF DIRECTORS**

**Ms. Savita Satish Gowda**

**Mr. Vijay Kirpalani**

**Mr. Lalit Misra**

**Mr. Mohan P. Kala**

**Dr. V. N. Badoni**

**Dr. Nivedita Patil**

**Mr. Drunal Shah**

**Mr. Harish Palecanda**

**Mr. Sanjay Shah**

**Managing Director**

**Whole Time Director**

**Whole Time Director**

**Director**

**Independent Director**

**Independent Director**

**Independent Director**

**Independent Director**

**Independent Director**

## **AUDITORS**

**M/s Shyam C. Agrawal & Company**

**Chartered Accountants**

## **BANKERS**

**1. Canara Bank**

**Prime Corporate Branch - I, Cuffe Parade, Mumbai**

**2. State Bank of India**

**Overseas Branch, Cuffe Parade, Mumbai**

**3. Axis Bank Ltd.**

**Andheri West Branch, Mumbai**

**4. Barclays Bank Plc,**

**Worli Branch, Mumbai**

**5. ING Vysya Bank Limited**

**Nariman Point Branch, Mumbai.**

## **COMPANY SECRETARIES**

**Mr. Samsad Alam Khan**


**COMPANY SECRETARIES (in Practice)**



**Jagdish Patel & Co.**

## Financial Highlights of Sharon Bio-Medicine Limited



₹ in Lacs

Particulars	2006 - 07	2007 - 08	2008 - 09	2009 - 10	2010 - 11
Turnover	17,100.45	33,461.60	41,979.12	49,649.88	60,604.66
Other Income	51.22	250.51	183.23	156.97	112.18
PBDIT	2,637.15	4,158.03	4,073.33	5,142.05	7,152.43
Interest	249.88	658.70	1,436.32	2,099.88	2,680.81
Depreciation	117.92	359.96	417.90	639.98	824.40
PBT	2,269.35	3,139.37	2,219.11	2,402.19	3,647.22
Income Tax	478.00	407.00	310.00	350.00	400.00
PAT	1,777.28	2,718.79	1,860.24	1,871.63	3,116.65
EPS	17.46	26.60	17.62	17.73	29.52









Dear Fellow Shareholders,

It is my privilege to present you the Company's performance for the year ended 30<sup>th</sup> June 2011. For the last 3 years your Company has been crossing century of a crore to surpass the Turnover. In this regard your Company has crossed ₹ 600 crores of Turnover which was ₹ 500 crores last year. Needless to say these achievements are possible by relentless focus on hard working, quality, control of costs, research and development centre work approvals, spreading the sales to more geographical areas and efficient management with complex situations by your company and its workforce.

Your Board of Directors, management and the employees are working hard to make this Company as global player and supply the products and services not only in India but to Regulated and non Regulated market in a big way. It is the policy of the Company to push the envelope on enablement the management undertake special programmes during the year with the objective of achieving greater engagement, better communication and appreciation driven culture in the Company. The employees who have done better performance in their respective fields are rewarded not only with certificate but also cash and shares option award.

From the product front your Company had added many products in case of formulation, Active Pharma Ingredients and Intermediates. In case of Toxicology, your Company has done pre clinical trials not only for Indian Company's but also for United State and Chinese Company. This is the result of getting Good Laboratory Practices Certification from Government of India, Dept Science & Technology New Delhi. Further, your Company could get Certification of Research & Development from Dept. Of Science & Technology, Govt. of India, New Delhi which was for Dehradun and Taloja, Navi Mumbai. This certification will help Company in getting not only 200% income tax benefits in the expenditure on Research & Development but add some good products in the Company fold along with the cost reduction in existing products. Looking forward, after getting the UK MHRA and Canadian Health Authorities approval for Dehradun Formulation facility last year, your Company is looking for United State America (USFDA) approval of its Dehradaun Formulation plant as well as Taloja, Navi Mumbai, Active Pharma Ingredient plant in immediate future.

You must have noticed the global economy saw trends of failing to gain strength during the year and the fear of doubled recession increased and the recovery seems still some time away before more self sustaining and significant growth patterns emerges. However, Pharma Industry is doing well not only with Indian Context but also in keeping global requirements which is seen through the publish data. In this regard your management is ensuring for a sustainable framework in which your Company can thrive in future with bigger markets and with new products.

Your Company is also looking for the opportunities in case of expanding its manufacturing operations in Uzbekistan wherein your Company has already done MOU with Uzbekistan Government for setting up of Active Pharma Ingredient plant and your Company is making all possible efforts to make this project successful after consulting with Govt. of Uzbekistan to get the all possible tax and monitory benefits and searching for investment to be done by the local Uzbekistan partners.